Regimmune Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series E
  • Latest Deal Amount
  • $6M
Latest Deal Amount
  • Investors
  • 35

Regimmune General Information

Description

Provider of immune regulatory therapeutics intended to develop novel therapeutics for a range of immune diseases and disorders. The company's technology focuses on therapeutic areas to target immune tolerance against specific disease-causing antigens through the induction of regulatory T cells, enabling patients to avail innovative and proper treatment for immune disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Delivery
Primary Office
  • 14-9 Nihonbashi Kodenma-cho Fine Building, 7th Floor
  • Tokyo, Chuou-ku 103-0001
  • Japan
+81 00-0000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Regimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series E) 12-May-2017 $6M 000.00 Completed Clinical Trials - General
7. Later Stage VC (Series D) 14-Feb-2014 00.00 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series C) 28-Mar-2012 00.00 000.00 Completed Clinical Trials - General
5. Grant 08-Dec-2008 0000 000.00 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 06-May-2008 000 000.00 Completed Pre-Clinical Trials
3. Grant 07-Aug-2007 00.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 21-Feb-2007 $4.2M $5.8M Completed Pre-Clinical Trials
1. Seed Round 15-Aug-2006 $1.6M $1.6M Completed Generating Revenue
To view Regimmune’s complete valuation and funding history, request access »

Regimmune Patents

Regimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190000760-A1 Nanoparticle-aqueous dispersion liquid of glycosphingolipid Abandoned 07-Dec-2015 00000000
JP-WO2017099079-A1 Glycosphingolipid nanoparticle aqueous dispersion Granted 07-Dec-2015 00000000
EP-3388059-A4 Nanoparticle-water dispersion liquid of glycosphingolipid Withdrawn 07-Dec-2015 00000000 0
EP-3388059-A1 Nanoparticle-water dispersion liquid of glycosphingolipid Withdrawn 07-Dec-2015 00000000
CA-2882553-A1 Preparation for preventing or treating type i diabetes Abandoned 22-Aug-2012 A61K38/28

Regimmune Executive Team (6)

Name Title Board Seat Contact Info
Kenzo Kosuda Chief Executive Officer, President, Board Member & Senior Vice President
Ping Zhong Ph.D Chief Technology Officer & Board Member
You’re viewing 2 of 6 executive team members. Get the full list »

Regimmune Board Members (8)

Name Representing Role Since
Hiroyuki Misawa Ph.D Miyako Capital Board Member 000 0000
Hiroyuki Tanaka Self Audit & Supervisory Board Member 000 0000
Joseph McCracken Self Board Member 000 0000
Ping Zhong Ph.D Regimmune Chief Technology Officer & Board Member 000 0000
Shirley Clayton Regimmune Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Regimmune Investors (35)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Hiroshima Venture Capital Venture Capital Minority 000 0000 000000 0
Iyo-Gin Capital Venture Capital Minority 000 0000 000000 0
Miyako Capital Venture Capital Minority 000 0000 000000 0
Ogaki Kyoritsu Bank Corporation Minority 000 0000 000000 0
Oita Venture Capital Other Minority 000 0000 000000 0
You’re viewing 5 of 35 investors. Get the full list »